Market evolution: Ophthalmic instruments (CN 90185090) — 2015–2025

Introduction

This report analyses the evolution of EU external trade in ophthalmic instruments and appliances classified under customs code 90185090. Over the 2015–2025 period, the EU consolidated its position as a net exporter in this high-value medical device segment, with exports growing at a faster pace than imports in value terms while import volumes surged. The period was characterised by strong growth, geographic diversification of suppliers, and a pronounced shift in trade dynamics driven by emerging Asian markets and pandemic-related shocks.

I. Robust Growth Fueled by Divergent Import and Export Dynamics

EU exports grew significantly in both value and volume, driven by high-value instruments

Over the full period, EU exports rose from €559.6 million (2015) to €967.0 million (2025), representing a 72.8% increase. Export volumes grew more moderately (+36.2%), indicating that the EU specialises increasingly in higher-value instruments. The average export price rose from €337,770 per tonne in 2015 to €428,512 per tonne in 2025 (+26.9%), reflecting a move up the value chain. This is consistent with the strong specialisation of key EU producers such as Germany, France, and Italy in advanced ophthalmic technologies.

Import volumes doubled while unit prices fell, signalling a shift toward more commoditised supply

Imports told a different story: their value grew 82.5% (from €346.6M to €632.4M), but volumes surged by 100.4% (from 1,487 tonnes to 2,980 tonnes). The average import price actually fell by 9.0%, from €233,084 to €212,171 per tonne. This divergence suggests that the EU increasingly sources lower-cost, potentially less sophisticated instruments from emerging suppliers, while continuing to export premium, high-precision devices.

EU domestic production expanded dramatically, underpinning export capacity

EU production volumes grew from under 1 million items to over 15 million items (+1,432%), while production value rose from €231.6 million to approximately €1.0 billion (+332%). This substantial expansion in manufacturing capacity — concentrated in Germany, which accounts for over a third of EU production — underpins the export surge and confirms the sector's strategic importance within the EU's medical device industry.

II. Geographic Rebalancing: The Rise of China and Emerging Partners

China emerged as the fastest-growing partner on both the import and export sides

The most striking structural shift in EU trade for this product was the rise of China. On the import side, Chinese shipments to the EU grew from just €8.5 million (2015) to €36.4 million (2025), a 328.9% increase. On the export side, EU exports to China surged from €84.9 million to €250.1 million (+194.4%), making China the EU's single largest export destination by 2025 — overtaking the United States. This dual growth reflects China's expanding healthcare infrastructure and manufacturing base, as well as the EU's success in supplying premium ophthalmic equipment to the Chinese market.

Traditional partners remain important, but their share is declining

The United States remained the EU's largest import source (€186.4M in 2025, +49.3%) and a major export market (€150.4M). Japan, the second-largest import source, showed modest growth (+6.5%). Switzerland saw its imports to the EU more than double (+140.6% to €105.7M), likely reflecting its role as a hub for high-precision medical device manufacturing. Meanwhile, Türkiye's imports to the EU grew by an extraordinary 1,091.5% (from €0.4M to €5.1M), signalling an emerging manufacturing base.

Import concentration decreased markedly, reflecting supplier diversification

The Herfindahl-Hirschman Index for import value fell from 2,401 to 1,627 (−32.2%), indicating a significant reduction in import concentration and greater geographic diversification of supply. This trend enhances the EU's resilience against single-source disruptions. In contrast, export concentration edged up slightly (from 951 to 1,057, +11.1%), as China came to dominate as an export destination.

III. Resilience and Vulnerability: Pandemic Shocks, Volatility, and Strategic Autonomy

The 2022 US import price shock was the most significant disruption in the period

The most notable shock event was an extreme price abnormality in EU imports from the United States in 2022, with an abnormality score of 899.9 and a 62.2% price shift. Given that US-sourced imports represented 35.3% of EU import value that year, this had a substantial impact on overall trade costs. This likely reflects post-COVID supply chain bottlenecks and inflationary pressures on high-precision medical equipment. Additional price shocks were detected in exports to Australia (2023, +111% shift) and the United Arab Emirates (2021, +50% shift), though these affected a smaller share of total trade.

Volatility varies widely across partners, with Mexico and Taiwan showing highest import instability

The coefficient of variation in import values highlights significant instability for certain partners. Mexico (CV: 1.05) and Taiwan (CV: 0.71) show the highest volatility, suggesting that sourcing from these origins carries greater uncertainty. On the export side, Australia (CV: 0.65) was the most volatile destination, while the United States (CV: 0.09) and Switzerland (CV: 0.15) represented exceptionally stable export markets. These patterns carry implications for supply chain risk management and market prioritisation.

The EU strengthened its net exporter position, with growing export propensity signalling strategic resilience

The EU's net import reliance shifted from −5.7% in 2015 to −52.4% in 2025, confirming a strengthening of the EU's net exporter status. At the same time, the export propensity increased from 111.1% to 134.9%, indicating that a growing share of EU production is being exported. The trade intensity index also rose from 105.4% to 117.4%, reflecting the sector's increasing integration into global value chains. Germany's dominance as the EU's leading exporter (€647.9M, representing roughly two-thirds of EU exports) underscores both the strength and the concentration risk of the EU's export base.

Conclusion

Between 2015 and 2025, the EU's ophthalmic instruments sector (CN 90185090) experienced strong, structurally meaningful growth. The EU consolidated its role as a major net exporter, with trade surpluses expanding and export values rising faster than import values. However, this growth was accompanied by a fundamental rebalancing of trade geography: China emerged as the EU's largest export market and a rapidly growing import supplier, while traditional partners like Japan and the United States saw more modest growth trajectories. The pandemic period (2020–2022) introduced significant price volatility, most dramatically in US-sourced imports, though the overall impact proved temporary. Looking ahead, the sector's strong specialisation in high-value instruments, combined with diversified supply sources, positions the EU favourably — though the concentration of exports toward China and the dominance of Germany as the EU's primary producer represent vulnerabilities worth monitoring.